ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
11 hedge funds and large institutions have $2.58M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
17% less capital invested
Capital invested by funds: $3.12M → $2.58M (-$532K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$731K |
| 2 |
Jane Street
New York
|
+$229K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$216K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$155K |
| 5 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$14.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$978K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$693K |
| 3 |
AIG
American International Group
New York
|
-$6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.33K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$854 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
LPL Financial
San Diego,
California
| $1.9M | +$731K | +34,226 | +69% |
|
|
2
Jane Street
New York
| $233K | +$229K | +10,737 | New |
|
|
3
Citadel Advisors
Miami,
Florida
| $220K | +$216K | +10,126 | New |
|
|
4
Royal Bank of Canada
Toronto,
Ontario, Canada
| $163K | +$155K | +7,257 | +2,903% |
|
|
LTFS
5
Ladenburg Thalmann Financial Services
Miami,
Florida
| $22K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $17K | -$2.33K | -109 | -12% |
|
|
GT
7
Glenmede Trust
Philadelphia,
Pennsylvania
| $15K | +$14.9K | +700 | New |
|
|
BBPWM
8
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $9K | – | – | – |
|
|
MFS
9
MSI Financial Services
Springfield,
Massachusetts
| $4K | – | – | – |
|
10
Creative Planning
Overland Park,
Kansas
| $2K | – | – | – |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $1K | -$854 | -40 | -40% |
|
|
VKH
12
Virtu KCG Holdings
New York
| – | -$978K | -34,235 | Closed |
|
|
13
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$693K | -24,256 | Closed |
|
|
AIG
14
American International Group
New York
| – | -$6K | -200 | Closed |
|
CNCR Hedge Fund Activity: Q1 2016 in Review
11 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q1 2016, worth a combined $2.58M — down 17% from $3.12M a quarter earlier.
Fund positioning in CNCR was balanced in Q1 2016: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was LPL Financial, adding an estimated $731K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $978K sold.
- 11 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $2.58M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q1 2016, down 17% quarter-over-quarter.
- 3 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q1 2016 and 3 closed out, a net change of 0 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q1 2016 was LPL Financial, an estimated $731K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q1 2016 was Virtu KCG Holdings, an estimated $978K sold.
Based on aggregated 13F filings for Q1 2016.